| The evolving role of next generation sequencing in myelodysplastic syndromes |
|
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| PNH Phenotypes and Their Genesis |
|
British Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Therapy-related myelodysplastic syndromes in the genomics era |
|
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
| Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes |
|
Cancer |
Myelodysplastic Syndromes (MDS) |
| Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes |
|
Cancer |
Myelodysplastic Syndromes (MDS) |
| Alcohol use is not a significant contributor to myelodysplastic syndromes |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
| Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
| Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
|
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
| Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. |
|
Cancer Med |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium |
|
Cancer Medicine |
Myelodysplastic Syndromes (MDS) |
